Multiomics Tumor Evolution Model of NSCLC

A Multiomics Study of Tumor Evolution Characteristics and Prognostic Model in Early-stage Non-small Cell Lung Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05352035

Enrollment

300

Registered

2022-04-28

Start date

2022-04-20

Completion date

2026-12-31

Last updated

2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

Non-small cell lung cancer, Multiomics analysis, Tumor evolution, Tumor immune microenvironment, Circulating tumor DNA, Radiomics, Prognostic model

Brief summary

The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Detailed description

Lung cancer is the leading cause of cancer-related death globally. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and surgery is still the main treatment strategy. This study will determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age ≥ 18 years old; 2. Early-stage NSCLC patients underwent radical surgical resection; 3. Sufficient tumor tissue and blood sample for study use; 4. Available clinical-pathologic data, imaging data and follow-up date; 5. Written informed consent.

Exclusion criteria

1. History of other malignant tumors; 2. Evidence of distant metastasis before surgery; 3. Insufficient tumor tissue or blood sample for study use; 4. Clinical-pathologic data, imaging data or follow-up date is not available; 5. Other judgments by the Investigator that the patient should not participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
Disease-free survival (DFS)	Through study completion, an average of 2 years	Time from randomization to disease recurrence or death from any cause.
Overall survival (OS)	Through study completion, an average of 2 years	Time from randomization to death from any cause.

Secondary

Measure	Time frame	Description
Relationship between translational biomarkers and clinical outcome	Through study completion, an average of 2 years	To evaluate if the translational biomarkers can be prediction tools for the clinical outcomes.

Countries

China

Contacts

Primary ContactKezhong Chen, M.D.

chenkezhong@pkuph.edu.cn+86-010-88326657

Backup ContactWenxiang Wang

wangwenxiang@stu.pku.edu.cn+86-010-88326657

Outcome results